"Auto\u0159i analyzuj\u00ED situaci v terapii kardiovaskul\u00E1rn\u00EDch chorob star\u0161\u00EDch nemocn\u00FDch, kter\u00E1 nen\u00ED zcela uspokojiv\u00E1 zvl\u00E1\u0161t\u011B ve smyslu indikace hypolipidemik. D\u00E1le jsou v \u010Dl\u00E1nku jednotliv\u011B rozeb\u00EDr\u00E1ny doporu\u010Dovan\u00E9 l\u00E9kov\u00E9 skupiny a jejich rizika vypl\u00FDvaj\u00EDc\u00ED pro stra\u0161\u00ED nemocn\u00E9 \u2013 je rozebr\u00E1na skupina inhibitor\u016F angiotenzin konvertuj\u00EDc\u00EDho enzymu, p\u0159\u00EDzniv\u00E9 ovlivn\u011Bn\u00ED endoteli\u00E1ln\u00ED dysfunkce touto skupinou se zd\u016Frazn\u011Bn\u00EDm nebezpe\u010D\u00ED vzniku hyperkal\u00E9mie, skupina antiagrega\u010Dn\u00EDch prepar\u00E1t\u016F, riziko gastrointestin\u00E1ln\u00EDho i dal\u0161\u00EDch druh\u016F krv\u00E1cen\u00ED a mo\u017Enosti vyu\u017Eit\u00ED dal\u0161\u00EDch typ\u016F antiagreganci\u00ED, skupina beta-blok\u00E1tor\u016F a jejich bradykardizuj\u00EDc\u00ED efekt a mo\u017Enosti z\u00E1va\u017En\u00FDch interakc\u00ED s dal\u0161\u00EDmi druhy pod\u00E1van\u00E9 medikace, skupina statin\u016F a jejich p\u0159\u00EDzniv\u00FD vliv na endoteli\u00E1ln\u00ED dysfunkci s rizikem vzniku myopati\u00ED a\u017E rhabdomyol\u00FDzy. Z dal\u0161\u00EDch skupin kardiovaskul\u00E1rn\u00EDch medikament\u016F je v\u011Bnov\u00E1na pozornost blok\u00E1tor\u016Fm kalciov\u00E9ho kan\u00E1lu, diuretik\u016Fm a digoxinu. V z\u00E1v\u011Bru \u010Dl\u00E1nku je vypracov\u00E1na tabulka mo\u017En\u00FDch klinick\u00FDch projev\u016F ne\u017E\u00E1douc\u00EDch vedlej\u0161\u00EDch \u00FA\u010Dink\u016F nej\u010Dast\u011Bji u\u017E\u00EDvan\u00FDch kardiovaskul\u00E1rn\u00EDch medikament\u016F u star\u0161\u00EDch nemocn\u00FDch." . "RIV/65269705:_____/11:#0001319!RIV12-MZ0-65269705" . . "RIV/65269705:_____/11:#0001319" . "Authors analyze the situation in the therapy of cardiovascular diseases \u2013 unsatisfactory situation especially from the dyslipidaemia point of view. Different groups of medications are discussed and their risks for elderly patients. Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction, but the risk of hyperpotassemia are showed. The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed. Attention is paid to calcium channel blockers, diuretics and digoxin. The table containing possible clinical symptoms of unwanted sideefect of most frequently used cardiovascular medications in elderly is added as the conclusion of the article."@en . . "Senio\u0159i a kardiovaskul\u00E1rn\u00ED medikace"@cs . . "6" . . "Weber, Pavel" . "Mat\u011Bjovsk\u00E1 Kube\u0161ov\u00E1, Hana" . "Meluz\u00EDnov\u00E1, Hana" . . . . "Senio\u0159i a kardiovaskul\u00E1rn\u00ED medikace" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "Senio\u0159i a kardiovaskul\u00E1rn\u00ED medikace"@cs . . "228822" . . "P(NS10029), S" . . . "Senio\u0159i a kardiovaskul\u00E1rn\u00ED medikace" . "10"^^ . . "angiotensin converting enzyme inhibitors"@en . "Seniors and cardiovascular madications"@en . . "4"^^ . "Seniors and cardiovascular madications"@en . . "CZ - \u010Cesk\u00E1 republika" . "57" . . . . "4"^^ . "Auto\u0159i analyzuj\u00ED situaci v terapii kardiovaskul\u00E1rn\u00EDch chorob star\u0161\u00EDch nemocn\u00FDch, kter\u00E1 nen\u00ED zcela uspokojiv\u00E1 zvl\u00E1\u0161t\u011B ve smyslu indikace hypolipidemik. D\u00E1le jsou v \u010Dl\u00E1nku jednotliv\u011B rozeb\u00EDr\u00E1ny doporu\u010Dovan\u00E9 l\u00E9kov\u00E9 skupiny a jejich rizika vypl\u00FDvaj\u00EDc\u00ED pro stra\u0161\u00ED nemocn\u00E9 \u2013 je rozebr\u00E1na skupina inhibitor\u016F angiotenzin konvertuj\u00EDc\u00EDho enzymu, p\u0159\u00EDzniv\u00E9 ovlivn\u011Bn\u00ED endoteli\u00E1ln\u00ED dysfunkce touto skupinou se zd\u016Frazn\u011Bn\u00EDm nebezpe\u010D\u00ED vzniku hyperkal\u00E9mie, skupina antiagrega\u010Dn\u00EDch prepar\u00E1t\u016F, riziko gastrointestin\u00E1ln\u00EDho i dal\u0161\u00EDch druh\u016F krv\u00E1cen\u00ED a mo\u017Enosti vyu\u017Eit\u00ED dal\u0161\u00EDch typ\u016F antiagreganci\u00ED, skupina beta-blok\u00E1tor\u016F a jejich bradykardizuj\u00EDc\u00ED efekt a mo\u017Enosti z\u00E1va\u017En\u00FDch interakc\u00ED s dal\u0161\u00EDmi druhy pod\u00E1van\u00E9 medikace, skupina statin\u016F a jejich p\u0159\u00EDzniv\u00FD vliv na endoteli\u00E1ln\u00ED dysfunkci s rizikem vzniku myopati\u00ED a\u017E rhabdomyol\u00FDzy. Z dal\u0161\u00EDch skupin kardiovaskul\u00E1rn\u00EDch medikament\u016F je v\u011Bnov\u00E1na pozornost blok\u00E1tor\u016Fm kalciov\u00E9ho kan\u00E1lu, diuretik\u016Fm a digoxinu. V z\u00E1v\u011Bru \u010Dl\u00E1nku je vypracov\u00E1na tabulka mo\u017En\u00FDch klinick\u00FDch projev\u016F ne\u017E\u00E1douc\u00EDch vedlej\u0161\u00EDch \u00FA\u010Dink\u016F nej\u010Dast\u011Bji u\u017E\u00EDvan\u00FDch kardiovaskul\u00E1rn\u00EDch medikament\u016F u star\u0161\u00EDch nemocn\u00FDch."@cs . "Mat\u011Bjovsk\u00FD, J." . "0042-773X" . "[D911A37939AB]" . .